It is a particularly aggressive breast cancer, which affects many women under 40 (about 40%): THE “triple negative” accounts for 15% of breast cancers. Since this Wednesday, December 14, a platform lists all the clinical trials around this disease, and gives access to patients so that they can claim them, inform Europe 1.
The triple negative is metastatic and considerably reduces the life expectancy of breast cancer, the median of which is 14 and a half months, recalls the HAS. But many clinical trials are underway to find an effective way to combat this disease, and they are now all listed and accessible from the site Klineo.
How does the platform work?
The protocol is then as follows: the patient connects to it, fills in her medical history and is offered trials with which her file is compatible. Then, his oncologist can transmit all the information.
Currently, less than 5% of breast cancer patients participate in clinical trials, and 20% of these in oncology fail because there are not enough applicants. It is therefore necessary to simplify the encounter between the patients and the options for the therapeutic tests in progress. Especially since according to Klineo, 70% of patients say they are ready to join a trial.